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Abstract
Objectives: The authors present a case report that proposes the use of cabergoline treatment in silent
ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-
functioning pituitary adenomas.
Design: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a
77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the
original tumor were performed.
Methods: The original tumor from the patient was studied by in situ hybridization and dopamine D2
receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas
from patients with Cushing's disease.
Results: The D2 receptor mRNA signal of the reported case was intense and of the same order of
magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was
twice that of control corticotroph adenomas and was close to that observed in prolactinomas.
Conclusions: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under
cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in
concentrations similar to those found in control prolactinomas. These results suggest that therapeutic
trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more
generally, non-functioning pituitary adenomas.
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Introduction
Silent corticotroph adenomas of the pituitary represent
2±7% of surgically removed adenomas (1). They are
defined as `non-functional' pituitary adenomas show-
ing an adrenocorticotropic hormone (ACTH) staining
at immunohistology. With the exception of rare cases in
which the `silent' characteristic of these adenomas is
due to the secretion of an ACTH molecule devoid of
biological activity (2), these adenomas are mainly
diagnosed at pathological examination. The proposed
treatment in those cases relies mainly on the surgical
removal of the tumor.
Dopamine agonists have been used in the treatment
of non-functioning pituitary adenomas and a relative
shrinkage of the tumor has been reported in 20% of the
cases (3). Cabergoline is a dopamine D2 receptor
agonist with a higher affinity and longer half-life
than bromocriptine. Its effectiveness and tolerance has
been demonstrated in the treatment of prolactinomas
(4) and growth-hormone (GH)-secreting adenoma (5),
but there are no consistent data on its efficacy in the
case of clinically functional ACTH-secreting or ACTH
silent adenomas.
We report herein the case of a relapsing ACTH silent
adenoma that was treated efficiently by the sole use of
cabergoline.
Case report
A 77-year-old man was referred to our hospital
following a sudden loss of visual acuity. Ophthalmo-
logical examination showed a bilateral visual fields
defect.
Magnetic resonance imaging (MRI) revealed a
pituitary tumor of 15 mm diameter with suprasellar
extension and chiasmatic compression. Indirect signs of
pituitary hemorrhage were noted.
Clinical examination did not show any sign of
hormonal hypersecretion. Biological endocrine tests
revealed a somatotroph and gonadotroph deficiency.
Thyrotroph function was normal. Corticotroph status
was normal: ACTH 8 h  90 pg=ml (10±90); total
cortisol  154mg=l (60±240); free urinary cortisol 
42mg=24 h (10±90). The tumor was believed to be
clinically non-functioning.
The tumor was successfully removed by trans-
sphenoidal surgery. Immunohistochemical study of
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tumoral tissue revealed a staining for ACTH in 90% of
the cells (Fig. 1). No staining was noted for other
markers including chromogranine, prolactin (PRL),
GH, luteinizing hormone, follicle-stimulating hormone
and a-SU. The diagnosis of silent corticotroph adenoma
was therefore established.
After surgery, complete recovery of hemianopsia was
obtained. The patient was treated for multiple pituitary
hormone deficiencies. The postoperative follow up and
yearly MRI revealed no residual tumor. Two years after
surgery, the patient was readmitted complaining of a
right palpebral ptosis with right hemicranial headache,
nausea and vomiting.
On physical examination, cranial nerves palsies (II,
III, IV and VI), disorientation and a mild gait ataxia
were noted. Pituitary MRI showed a recurrent mass
extending to the right cavernous sinus without
compression of the optic chiasm; the maximum
tumor diameter was 30 mm (Fig. 2A).
Due to the poor general condition of the patient,
further surgery was contraindicated. The patient
refused stereotactic pituitary irradiation. Medical treat-
ment with cabergoline was then started at a final dose
of 0.5 mg every 2 days.
Four months later, MRI demonstrated a significant
shrinkage of the adenoma with a maximal diameter
reduced to 21 mm. This was associated with an
improvement of the cranial nerve palsies. One year
after, tumor diameter was further reduced to 17 mm
(Fig. 2B) and ocular examination showed a nearly
complete recovery of the ocular nerve functions. At 2
years' follow up, the size of the adenoma remains stable
under cabergoline treatment and the patient remains
asymptomatic.
Figure 1 Immunohistochemical study of pituitary tumoral tissue.
(A) Blank section of the patient's pituitary macroadenoma. (B)
Immunohistochemistry revealed a staining for ACTH in 90% of
the tumoral cells.
Figure 2 MRI of the pituitary (frontal views). (A) At tumor recurrence (2 years after surgery) the tumor measures 30 mm and invades the
right cavernous sinus. (B) After 1 year of cabergoline treatment (0.5 mg every 2 days) there is a significant shrinkage of the tumor and
nearly complete disappearance of the clinical symptoms.




The tumor was collected rapidly after excision and was
stored in aluminum foil at 280 8C. Four macropro-
lactinomas (P1±P4) known to exhibit a significant D2
mRNA signal using in situ hybridization were collected
under the same conditions and used as positive
controls. Acute administration of bromocriptine at a
dose of 2.5 mg in patients bearing P2 and P4
suppressed the mean plasma PRL concentration by
more than 50% within 8 h. Two additional cortico-
troph macroadenomas obtained from patients with
Cushing's disease (C1, C2) were also studied.
In situ hybridization
All adenomas were hybridized during the same
experiment. The protocol used has been described
previously (6). Briefly, antisense and sense radiolabelled
cRNA probes were prepared by in vitro transcription of
the DNA template from plasmid pCMV5 constructs
containing the cDNA encoding D2 receptor (2300 bp).
The antisense probe recognized indifferently the two D2
receptor mRNA isoforms generated by alternative
splicing. Plasmids containing the coding region of D2
receptor were generously provided by Dr Caron (Duke
University, USA).
After hybridization, slides were exposed in contact
with I-Max film for 1 month, then coated with Ilford
K-5 emulsion and exposed for 3 months.
Control for specificity of the hybridization signal was
performed using the corresponding sense probe for
each section studied. No weak spurious or non-specific
signal was observed when the slides were hybridized
with the sense probe (Fig. 3).
Quantitative analysis of mRNA signal was performed
at the macroscopic level (autoradiogram) using an
image analyser system (Biocom, Les Ulis, France) fitted
with a densitometric image system. A CDD camera
provided a computerized image on a video monitor on
which the regions of interest were delineated. The
optical density (OD) was measured among each
adenoma (in the whole section of each tumor). We
measured the ODs of the antisense and the sense
mRNA signal. The OD of the sense signal was then
subtracted from the OD of the antisense signal. The OD
of the sense signal was equal to zero or very weak.
Dopamine D2 receptor autoradiography
The protocol used has been described previously (7).
Briefly, slides were preincubated and then incubated in
the incubation buffer for 30 min at room temperature
in the presence of the radioligand [125I]-iodosulpride at
a concentration of 0.5 nM (2000 Ci/mmol). Because
this study was performed in vitro on pituitary tissue,
where mainly D2 receptors are present, the use of
iodosulpride, which is less specific than cabergoline,
was considered satisfactory (8). Non-specific binding
was determined on adjacent sections after addition of
unlabelled competitor to the incubation medium
(1025 M sulpride). After washing, the sections were
then exposed on 3H-Hyperfilm (Amersham Bucks,
UK) for 1 month. The autoradiograms were quanti-
fied using an image analyzer system by measuring
the mean OD for each tissue sample. The OD of the




Using macroautoradiography (Fig. 4), the D2 receptor
mRNA signal in the four prolactinomas studied was
variable. A significant D2 receptor mRNA signal was
found in the two control corticotroph adenomas (C1,
C2). However, the intensity of the signal in these was
approximately half of that observed in prolactinomas.
Figure 3 In situ hybridization for dopamine D2 receptor mRNA in
the silent corticotroph adenoma (microautoradiography). (A)
Hybridisation with the antisense probe shows dopamine D2
receptor mRNA in tumor cells. Scale bar  10mm: (B) Control for
specificity of the labeling with the sense probe. Only weak
background signal is observed. Scale bar  10mm:
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By contrast, the D2 receptor mRNA signal in the
adenoma of case reported (C3) was intense and of the
same order of magnitude than that observed in
prolactinomas.
Dopamine D2 receptor autoradiography
The prolactinomas exhibited a signal of variable
intensity (Fig. 5). The two control corticotroph
adenomas (C1, C2) showed a weak signal that was
approximately one third of the median value observed
in the prolactinomas. As a whole, the intensity of the
signal in the tumor of the patient presented here (C3)
was twice that of control corticotroph adenomas and
was close to the range of values observed in prolacti-
nomas.
Using macroautoradiography (Fig. 6), a weak dopa-
mine D2 receptor signal appeared to be distributed
along the whole surface of control corticotrophs (C1±
C2). On the contrary, in adenoma C3, the distribution
of D2 receptor binding sites was heterogeneous and
some areas displayed an intense signal comparable to
that seen in prolactinomas.
Discussion
We report herein the first case of an ACTH silent
adenoma showing a significant shrinkage under
cabergoline treatment. The efficacy of this treatment
was believed to be due to the presence of dopamine D2
receptors in the tumor cells.
ACTH silent adenomas are clinically non-functioning
tumors that are usually diagnosed at immunohistologic
examination of the tumorous tissues after surgical
treatment. Although there are few reports about these
tumors in the literature, they may represent 2±7% of
all surgically treated adenomas (1). They present the
same histological and ultrastructural features of ACTH-
secreting adenomas of the pituitary in Cushing's
disease (9). Different hypotheses have been proposed
to explain the lack of clinical symptomatology of these
tumors such as the defective packaging of tumor ACTH
Figure 4 Quantitative in situ hybridization
analysis of dopamine D2 receptor mRNA.
Control prolactinomas (P 1±4), control
corticotroph adenomas (C1, C2) and the
adenoma of the reported case (C3).
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and the increased intracellular degradation of the
hormone (10, 11). A few cases of tumors secreting a
biologically inactive hormone have also been described
(2).
Because these adenomas do not elicit a Cushing's
disease, the main goal of the treatment is to obtain a
reduction in tumor size. Surgery has been the main
therapeutic approach in all described cases. To the best
of our knowledge, only one report regarding the
effectiveness of bromocriptine in obtaining murine
tumor shrinkage in such cases has been published
(22). In another report, bromocriptine was used in a
patient to prevent the recurrence of an aggressive silent
corticotroph adenoma (23). We did not find any report
with cabergoline.
However, dopamine agonists have been successfully
used for controling hormonal hypersecretion in some
ACTH secreting adenomas responsible for Cushing's
disease (12, 13) and a few cases of tumor shrinkage
have also been reported (14).
Five different dopamine receptors have been cloned
so far. These receptors are divided in two groups by
their molecular, biochemical and pharmacological
differences (15). The first group comprises the D1 and
D5 receptors and the second group the D2, D3 and D4
receptors. In the pituitary, hormonal response to
dopamine agonists is related to the activity of the D2
receptor (16). The latter belongs to the family of the G
protein-coupled receptors and acts through the inhibi-
tion of the AMP cyclase enzyme. Alternative splicing of
the gene encoding the D2 receptor leads to two
subtypes of this receptor, the short isoform (D2Rs)
and the long isoform (D2Rl) (17).
The relation between the presence of the D2 receptor
and the therapeutic response of pituitary adenomas to
dopamine agonists has been studied in a variety of
tumors. In prolactinomas, the presence of numerous
D2 receptors explains the good therapeutic response of
these tumors to dopamine agonists. Drug resistance in
some of these adenomas may be explained either by the
Figure 5 Quantitative analysis of binding
of the dopamine D2 receptor. Control
prolactinomas (P 1±4), control cortico-
troph adenomas (C1, C2) and the
adenoma of the reported case (C3).
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absence or the reduced amount of these receptors (19)
or by their functional inactivity (18). Treatment with
dopamine agonists not only reduces the hormonal
secretion, but also reduces the tumor size. Tumor
shrinkage seems to be related to the disappearance of
the rough endoplasmic reticulum and of the Golgi
apparatus which leads to a reduction of tumor cell size
(20).
Before somatostatin analogs, dopamine agonists
were the only medical treatment for GH-secreting
adenomas. Dopamine receptors have also been demon-
strated in GH-secreting cells, but the biological and
tumoral response to dopamine agonists is not as
marked as in prolactinomas. This reduced sensitivity
may be due to a difference in the abundance of D2
receptors as well as their structural and functional
properties and a reduced AC inhibition. However, our
data (5) demonstrates that despite a reduced number of
D2 receptors and/or reduced effectiveness in GH-
secreting adenomas, the resistance of these tumors to
dopamine agonists can be overcome in a number of
cases with the use of high affinity agonists, such as
cabergoline.
In non-functioning adenomas, D2 receptors have
been demonstrated in a large number of studied
adenomas, but partial tumor shrinkage has been
reported in only 20% of the published cases (3). Drug
resistance in these adenomas may be due to the same
D2 receptor abnormalities than in GH-secreting ade-
nomas. A recent study suggests that cells presenting
the short subtype receptor (D2Rs) may present a better
inhibitory response to DA, at least in vitro (21).
Less data are available about the efficacy of
dopamine agonists in ACTH-secreting adenomas. Hor-
monal normalization has been described in some cases
(12, 13). Dopamine agonists have also shown a growth
inhibitory effect and provoked in vitro cellular apoptosis
in murine ACTH-secreting pituitary adenoma cells
(22). Interestingly, a report has recently demonstrated
a complete remission of a Nelson's syndrome following
bilateral adrenalectomy, after 1 year of treatment with
cabergoline (24).
Our case is the first report of a silent ACTH adenoma
treated by cabergoline. The dramatic tumor shrinkage
in our case is likely due to the cabergoline therapy. Our
in vitro studies on tumor tissue from the original
adenoma provided evidence of D2 receptor expression
within the tumor with an intensity roughly comparable
to that found in control prolactinomas. In contrast, no
or only weak expression of D2 receptor was found
on control corticotroph adenomas of patients with
Cushing's disease.
One might speculate that the partial shrinkage of the
tumor under cabergoline treatment is due to the
heterogeneous distribution of D2 receptors in tumor
cells as demonstrated by in situ hybridization and
Figure 6 In vitro autoradiographical distribution of [125I]-iodosulpride binding (scale: line  1 mm: (A) Total binding in a control
prolactinoma (P4). An heterogeneous signal is observed within the tumor. (B) Weak total binding in a control corticotroph adenoma (C1).
(C) Total binding in the tumor of the patient (C3). (D) Control for non-specific binding in the tumor of the patient (C3). No residual binding is
seen in the presence of 1025 M sulpride.
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binding studies, although we can not exclude that the
recurring tumor originated from a clone expressing the
D2 receptor differently.
Whether cabergoline may be as efficient in other
cases of ACTH silent adenomas and, more generally,
non-functioning adenomas is to be assessed. Thera-
peutic trials may be performed in cases of recurring
adenomas or when surgery is contraindicated. In vivo
scintigraphy using D2 agonists (25, 26), or in vitro D2
receptor studies in recurring tumors may allow a better
selectivity in the therapeutic choice.
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